Boomerang Medical, a bioelectronic medicine company, has raised $15 million in series A financing.
The company plans to use the proceeds to fund clinical studies on the use of neuromodulation as a treatment for autoimmune diseases. The studies will begin with a focus on inflammatory bowel disease, according to a Nov. 1 Boomerang Medical news release.
Arboretum Ventures and Hatteras Venture Partners led the funding round. The company has now raised a total of $18 million.